Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for the treatment of fatty liver disease

Inactive Publication Date: 2014-09-18
GOLDEN BIOTECH
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method of treating fatty liver disease in patients by administering a specific chemical compound. This compound is a type of compound called a cyclohexenone, which has certain properties that make it useful in treating fatty liver disease. The patent also mentions that the cyclohexenone compound can be combined with other ingredients to make the treatment more effective.

Problems solved by technology

This means that NASH can ultimately lead to scarring of the liver (fibrosis) and then irreversible, advanced scarring (cirrhosis).
There are few therapeutically effective drugs for treating fatty liver.
Exercise and controlled diet are recommended, but these are not so effective in treating fatty liver.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for the treatment of fatty liver disease
  • Method for the treatment of fatty liver disease
  • Method for the treatment of fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

example

Example 1

Isolation of Exemplary Cyclohexenone Compounds

[0056]100 g of mycelia, fruiting bodies or mixture of both from A. camphorata were placed into a flask. A proper amount of water and alcohol (70-100% alcohol solution) was added into the flask and were stirred at 20-25 degrees Celsius (° C.) for at least 1 hour. The solution was filtered through a filter and a 0.45 μm (micrometer) membrane and the filtrate was collected as the extract. The filtrate of A. camphorata was subjected to a High Performance Liquid chromatography (HPLC). The HPLC was performed using a RP18 column, methanol (A) and 0.1˜0.5% acetic acid (B) as the mobile phase, with gradient of 0˜10 min in 95%˜20% B, 10-20 min in 20%˜10% B, 20˜35 min in 10%˜10% B, 35˜40 min in 10%˜95% B, at a flow rate of 1 ml / min. The effluent was monitored with a UV-visible detector.

[0057]The fractions at 25˜30 min were collected and concentrated to yield Compound 1, 4-hydroxy-2,3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-dodeca-2,6,10-tri...

example 2

Reduction of Fatty Liver Condition by Compound 1 (4-hydroxy-2,3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-dodeca-2,6-10-trienyl)-cyclohex-2-enone)

[0063]In order to simulate an unhealthy diet tendency in humans, such as excess consumption of high caloric food, the example constructs an animal model using rats fed a high fat diet to evaluate the effects of chronic liver injury. Thereafter, the effects can be revealed through biochemical assays to prove the fatty liver reduction of exemplary compounds provided herein such as Compound 1,4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6-10-trienyl)-cyclohex-2-enone (the test compound).

[0064]The assay simulates liver disease caused by a high fat diet through a “Metabolic Syndrome” model. That is, the model is different from conventional chemical induced models caused by toxic components such as CCl4. This model is distinguishable from the models caused by virus or alcohol.

[0065]The establishment of a long term high-fat diet is d...

example 3

Reduction of Fatty Liver Condition by the Composition Comprising Compound 1 and Ergosterol

[0089]Except for the testing groups and treatment schedule, the materials and processes of Metabolic Syndrome” model, Histology analysis, Whole blood and plasma biochemistry and Fatty Liver Disease Caused by Non-Chemical Injury are similar to those stated in Example 2.

[0090]In control group (group A), six rats were fed with vehicle (corn oil from Sigma chemical co.) by means of stomach tubes. Six rats in group B were orally administered vehicle and the test compound (Compound 1) at a dose of 48 mg / kg twice a day (96 mg / kg per day) and ergosterol at a dose of 12 mg / kg twice a day (24 mg / kg per day). Six mice in group C were orally administered vehicle and the test compound (Compound 1) at a dose of 48 mg / kg twice a day (96 mg / kg per day).

[0091]Table 1 below shows the study timetable summary.

TABLE 1The timetable of the studyTimeProcessDay 0BirthDay 2STZ treatmentDay 28Feeding high fat dietDay 62R...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The invention provides a method of treating, inhibiting and / or preventing fatty liver disease in a patient in need thereof, comprising administering an effective amount of a cyclohexenone compound of the following formula (I) to said patient,

Description

FIELD OF THE INVENTION[0001]The present invention relates to a method for the treatment of fatty liver disease, and more particularly, to a method of administering a cyclohexenone compound.BACKGROUND OF THE INVENTION[0002]Fatty liver refers to a pathogenic condition where fat comprises more than 5% of the total weight of the liver. Fatty liver and steatohepatitis are frequently found in people who intake excessive alcohols and who have obesity, diabetes, hyperlipidemia, etc. Nonalcoholic fatty liver disease (NAFLD) refers to a wide spectrum of liver disease ranging from simple fatty liver (steatosis), to nonalcoholic steatohepatitis (NASH), to cirrhosis (irreversible, advanced scarring of the liver). All of the stages of NAFLD have in common the accumulation of fat (fatty infiltration) in the liver cells (hepatocytes). In NASH, the fat accumulation is associated with varying degrees of inflammation (hepatitis) and scarring (fibrosis) of the liver. The NAFLD spectrum is thought to be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/122A61K31/575
CPCA61K31/575A61K31/122A61K9/0056A61K9/0078A61K9/4875A61P1/00A61P1/16A61P43/00A61K2300/00A61K36/07
Inventor LIU, SHENG-YUNGWEN, WU-CHECHEN, CHIH-MING
Owner GOLDEN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com